Effect of anti-VEGFR-3 treatment on tumor-associated mortality and tumor growth post–allo-HSCT in the C57BL/6 → BALB/c model. BALB/c allo-HSCT recipients were injected IV with 5 × 106 C57BL/6 bone marrow cells and 5 × 105 A20-TGL tumor cells. One milligram per mouse of control antibody or mF4-31c1 antibody was injected every second day from day 0 to day +16. (A) Schematic representation of the C57BL/6 → BALB/c GVHD model used for tumor experiments. (B-C) Allo-HSCT with bone marrow only; no T cells were given. (B) Survival curve of control antibody and mF4-31c1–treated allo-HSCT recipients (n = 4 per group). Data from one representative experiment are shown; analysis was done with the log-rank test. (C) Average radiance data of control antibody and mF4-31c1–treated allo-HSCT recipients (n = 4 per group). (D-E) Allo-HSCT with bone marrow and additional 3 × 105 donor splenic T cells. (D) Survival curve of control antibody and mF4-31c1–treated allo-HSCT recipients (n = 4 per group). Data from one representative experiment are shown; analysis was done with the log-rank test. (E) Average radiance data of control antibody and mF4-31c1–treated allo-HSCT recipients (n = 4 per group). Error bars indicate mean ± SEM; significance was tested with an unpaired Student t test. Avg, average.
